Search results
Results from the WOW.Com Content Network
This is an accepted version of this page This is the latest accepted revision, reviewed on 6 October 2024. Class of vaccines against human papillomavirus HPV vaccine Vaccine description Target Human papillomavirus (HPV) Vaccine type Protein subunit Clinical data Trade names Gardasil, others AHFS / Drugs.com Monograph MedlinePlus a615028 License data US DailyMed: Human papillomavirus vaccine ...
There are six prophylactic HPV vaccines licensed for use: the bivalent vaccines Cervarix, Cecolin, and Walrinvax; the quadrivalent vaccines Cervavax and Gardasil; and the nonavalent vaccine Gardasil 9. [27] All HPV vaccines protect against at least HPV types 16 and 18, which cause the greatest risk of cervical cancer.
Gardasil is an HPV vaccine for use in the prevention of certain strains of human papillomavirus (HPV). [10] [7] [8] [9] [11] It was developed by Merck & Co. [12] High-risk human papilloma virus (hr-HPV) genital infection is the most common sexually transmitted infection among women. [13]
The company said it plans to conduct two separate trials testing Gardasil 9 in men and women 16-26 years old to examine whether a single dose of the vaccine provides comparable long-term ...
In the U.S., the HPV vaccine has been recommended since 2006 for girls at age 11 or 12, and since 2011 for boys the same age. Catch-up shots are recommended for anyone through age 26 who hasn’t ...
Overall, 2023 coverage was similar to 2022, with 76.8% of all teens between ages 13 and 17 receiving at least one dose of the HPV vaccine compared to 76.0% in 2022, the report found.
Sample vaccination schedules discussed by the World Health Organization show a developed country using a schedule which extends over the first five years of a child's life and uses vaccines which cost over $700 including administration costs while a developing country uses a schedule providing vaccines in the first 9 months of life and costing ...
There is a vaccine for HPV that can prevent over 90% of HPV-related cancers. In 2022, however, just 38.6% of young people in the U.S. had received at least one of the two recommended doses.